NR
Nurix Therapeutics, Inc.
NRIX · NASDAQ
$25.67 +0.43% (+$0.11)
1M -3.27%
Market Cap $2.64B
P/E Ratio -
Div. Yield -
ROE 76.09%
Piotroski F-Score Weak
2/9Valuation
9 /100
Expensive P/B 6.55x
P/S 71.73x
EV/EBITDA N/A
Growth
100 /100
Growing Book val. growth 21.05%
Rev. growth 29.55%
FCF growth N/A
Profitability
0 /100
Weak Net margin 928.44%
Op. margin 982.37%
FCF margin 828.28%
Quality
1 /100
Poor ROE 76.09%
ROA 63.74%
Asset turnover 0.07x
Debt
100 /100
Low Current ratio 6.34x
Debt/Equity 0.14x
Net debt/EBITDA N/A
Stability
29 /100
Unstable Rev. volatility 65.14%
EPS volatility 20.75%
Profitable years 0
Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej
Zapytaj StockBota o NRIX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Arthur T. Sands
Employees
317
Headquarters
Brisbane
Nadchodzące wydarzenia
08 PAŹ
Earnings
Upcoming earnings report